PD Dr. Norbert Meidenbauer

Medizinische Fakultät Department of Medicine 5 – Haematology and Oncology

The WERA cancer center matrix: Strategic management of patient access to precision oncology in a large and mostly rural area of Germany (2024) Krebs M, Haller F, Spörl S, Gerhard-Hartmann E, Utpatel K, Maurus K, Kunzmann V, et al. Journal article ERBB2/ ERBB3-mutated S100/ SOX10-positive unclassified high-grade uterine sarcoma: first detailed description of a novel entity (2024) Agaimy A, Dermawan JK, Haller F, Semrau S, Meidenbauer N, Stöhr R, Lax S, et al. Journal article Machine Learning-Supported Diagnosis of Small Blue Round Cell Sarcomas Using Targeted RNA Sequencing. (2024) Schlieben LD, Carta MG, Moskalev E, Stöhr R, Metzler M, Besendörfer M, Meidenbauer N, et al. Journal article Extra-abdominal and intra-abdominal FET::CREM fusion mesenchymal neoplasms: comparative clinicopathological study of 9 new cases further supporting a distinct potentially aggressive sarcoma and report of novel sites (2024) Agaimy A, Blakely M, Breimer GE, Hölsken A, Koppes SA, Meidenbauer N, Rijken JA, et al. Journal article Determinants Affecting the Clinical Implementation of a Molecularly Informed Molecular Tumor Board Recommendation: Experience from a Tertiary Cancer Center. (2023) Tögel L, Schubart C, Lettmaier S, Neufert C, Hoyer J, Wolff K, Moskalev E, et al. Journal article Chemoradiotherapy plus hyperthermia (CRTH) versus chemoradiotherapy (CRT) alone in neoadjuvant treatment of soft tissue sarcoma: tumor response, treatment toxicity and disease control (2023) Willner A, Agaimy A, Fechner K, Ott O, Denz A, Weissmann T, Meidenbauer N, et al. Journal article Identification of Disparities in Personalized Cancer Care—A Joint Approach of the German WERA Consortium (2022) Lüke F, Haller F, Utpatel K, Krebs M, Meidenbauer N, Scheiter A, Spörl S, et al. Journal article Recording of the regional Origin Areas of Patients from the Molecular Tumor Board to Identify the "white Spots" in the Service Area - A joint Initiative of the Bavarian CCC WERA Alliance (2022) Lueke F, Haller F, Utpatel K, Krebs M, Meidenbauer N, Scheiter A, Spörl S, et al. Conference contribution Drug Therapy Safety with new oral Antitumor Agents for the Therapy of Prostate and Renal Cell Carcinoma: Findings from the AMBORA Study (2022) Cuba L, Schlichtig K, Dürr P, Bellut L, Meidenbauer N, Kunath F, Goebell P, et al. Conference contribution Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial (2022) Zimmermann H, Koenecke C, Dreyling MH, Pott C, Duehrsen U, Hahn D, Meidenbauer N, et al. Journal article